The company has entered into a collaboration with a research group at University of Glasgow, UK, with the objective of performing an exploratory phase 2 study with rabeximod in patients with rheumatoid arthritis.
”We are extremely pleased to be able to announce this strategically important collaboration around rabeximod. It is an honor that Cyxone now can establish this research collaboration with the University of Glasgow and their world-leading experts within RA research. With this, we will be able to learn much more about rabeximod and how the drug acts in the body by accessing the advanced state-of-the-art technologies that the scientists in Glasgow use in their research. The collaboration also provides access to the wider group of expertise that are in the British RA research consortium RACE, where a number of leading key opinion leaders take part, many of them already acquainted with Cyxone’s project. We are really looking forward to this very important collaboration, and the learnings that will come out of it,” says Carl-Magnus Högerkorp, CEO of Cyxone.
Photo of Carl-Magnus Högerkorp: Cyxone
